CNSP (CNS Pharmaceuticals) EPS (Basic) : $-70.72 (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CNS Pharmaceuticals EPS (Basic)?

CNS Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.25. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-70.72.

CNS Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.25. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-70.72.

CNS Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2024 was $-0.25. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -70.72.

During the past 3 years, the average EPS without NRI Growth Rate was 16.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, CNS Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 16.40% per year. The lowest was -10.10% per year. And the median was 0.70% per year.

CNS Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for CNS Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNS Pharmaceuticals EPS (Basic) Chart

CNS Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-420.00

-855.00

-825.00

-561.00

-500.00

CNS Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-54.14	-43.25	-20.50	-6.72	-0.25

CNS Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

CNS Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-18.851	-	0)	/	0.038
	=	-496.08

CNS Pharmaceuticals's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-5.606	-	0)	/	22.181
	=	-0.25

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.72

CNS Pharmaceuticals (NAS:CNSP) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

CNS Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of CNS Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

CNS Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNS Pharmaceuticals Inc (NAS:CNSP) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2100 West Loop South, Suite 900, Houston, TX, USA, 77027

Website

https://www.cnspharma.com

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Executives

Christopher Downs	officer: Chief Financial Officer	31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
John M Climaco	director, officer: Chief Executive Officer	PO BOX 326, PARK CITY UT 84060
Carl Anthony Evans	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Jerzy Gumulka	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027
Bettina M. Cockroft	director	C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Waldemar Priebe	10 percent owner	2575 W. BELLFORT, SUITE 333, HOUSTON TX 77054
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Jeffry R. Keyes	director	13950 STOWE DRIVE, POWAY CA 92064-8803
Andrzej Andraczke	director	C/O CNS PHARMACEUTICALS, INC., 2100 WEST LOOP SOUTH STE 900, HOUSTON TX 77027